biphasic insulin aspart (Novo Nordisk)

Biphasic insulin aspart is a premixed insulin analogue suspension consisting of rapid-acting soluble insulin aspart and intermediate-acting protamine-crystallized insulin aspart. This dual-action formulation is designed to provide both immediate postprandial glucose control and sustained basal glycemic coverage. Developed by Novo Nordisk and marketed under the brand name NovoMix, it is primarily indicated for the treatment of diabetes mellitus in adults, adolescents, and children. In the specific clinical context of a pilot randomized trial conducted by Consorci Sanitari Integral, biphasic insulin aspart is being evaluated as a simplified premixed insulin therapy option for patients aged 65 and older with poorly controlled type 2 diabetes mellitus, comparing its efficacy and safety against more complex basal-bolus insulin regimens.

Brand names

NovoMixNovoMix 30NovoMix30NovoMix-30NovoMix 50NovoMix50NovoMix-50NovoMix 70NovoMix70NovoMix-70

Other names

BIAspinsulin aspart biphasicBiphasic Insulin Aspart 30Biphasic Insulin Aspart 50